GNAO1 and hepatocellular carcinoma: In the Kaplan–Meier plotter database, the RFS analysis of all HCC patients (n = 316), stage I-II (n = 228), and stage III-IV (n = 70) revealed that patients with high mRNA expression of GNAO1 had more favorable RFS than those with low GNAO1 expression (all p < 0.05; Figures 3(a)–3(c)).